Hematology-Oncology
USP22 as a Therapeutic Vulnerability in KMT2A-Rearranged Acute Leukemia: Regulating MEIS1 Stability and Oncogenic Transcription
Recent evidence identifies USP22 as a key regulator of MEIS1 protein stability, revealing a promising therapeutic target to disrupt leukemogenic transcription in KMT2Ar acute leukemia.
